Tracking measles cases in the United States

Measles cases in the US surged to a record high in 2025 with three deaths—the first US measles deaths since 2015—and transmission has continued into 2026 with more cases in January than is typical for a full year. A West Texas outbreak accounted for at least a third of 2025 cases, a South Carolina outbreak became the largest in decades, and declining MMR coverage among kindergarteners (from 95.2% in 2019–2020 to 92.5% in 2024–2025, leaving ~286,000 children at risk) raises the possibility the US could lose measles elimination status, which would have implications for public-health policy, vaccine demand and related healthcare services.

Analysis

Market structure: Short-term winners are vaccine manufacturers (Merck - MRK) and distribution channels (McKesson, Cardinal Health) plus retail clinic operators (CVS, WBA) and diagnostics (Quest Diagnostics - DGX, LabCorp - LH) because renewed vaccination and testing demand lifts volumes. Losers are discretionary travel and event stocks if outbreaks trigger localized advisories; insurers (UNH, ANTM) face modest elevated pediatric inpatient claims. Incremental demand is measurable: CDC data cites ~286k underimmunized kindergarteners; a coordinated catch-up campaign could add 0.3–1.0M incremental MMR doses over 6–12 months (low single-digit percent uplift to vaccine unit volumes).

Risk assessment: Tail risks include PAHO revoking US elimination status at its April meeting (catalyst) or vaccine supply bottlenecks prompting emergency procurement and price controls; both could re-rate manufacturers and distributors. Immediate (days) risks center on weekly CDC case data and state-level mandates; short-term (weeks–months) on supply chain and clinic capacity; long-term (quarters) on structural vaccine hesitancy trends and policy changes. Hidden dependencies: school-entry law changes and state funding for clinics could materially amplify demand quickly.

Trade implications: Direct plays: establish a tactical 2–3% long in MRK (3–6 month horizon) ahead of potential government purchases and sentiment rerating; add 1–2% split long in CVS and WBA for near-term clinic volume, and a 0.5% directional call-spread on DGX for testing volume. Pair trade: long MRK vs short Delta (DAL) 0.5–1% to hedge downside in travel if outbreaks worsen. Use options to define risk: 3–6 month call spreads rather than naked calls.

Contrarian angles: Consensus underestimates policy upside — loss of elimination status would likely trigger multi-state vaccination mandates and one-time government purchases, a structural boost larger than incremental retail clinic sales. Conversely, the market may over-rotate into defensives; that presents a fade opportunity to sell long-dated Treasury exposure if outbreaks remain geographically contained. Historical parallels (2019 NY outbreaks) show sharp, short-lived volume spikes followed by normalization within 6–12 months; position sizing should reflect high odds of mean reversion.

Key Decisions for Investors

• Establish a tactical 2–3% long position in Merck (MRK) with a 3–6 month horizon; set sell-target at +12–18% and stop-loss at -10%. Increase to 4–5% only if PAHO revokes elimination status or CDC reports >1,000 US cases in a month.
• Deploy a 1% long in CVS Health (CVS) and a 1% long in Walgreens Boots Alliance (WBA) for a 4–8 week trade to capture clinic/vaccine foot traffic; exit if weekly new US cases decline for two consecutive weeks or if share price gains >12%.
• Buy a 3-month call spread on Quest Diagnostics (DGX) equal to ~0.5% portfolio notional (e.g., 1x 5–10% OTM call spread) to express testing demand; close/roll if implied vol >50% or case growth plateaus for 3 weeks.
• Implement a 0.5–1% pair trade: long MRK vs short Delta Air Lines (DAL) to hedge contagion-driven travel weakness; unwind if DAL outperforms MRK by >15% or if CDC withdraws travel advisories.
• Monitor two binary catalysts in next 60–90 days: PAHO meeting outcome (April) and weekly CDC national case count. If PAHO revokes elimination status or monthly US cases exceed 1,000, add to vaccine/distributor exposure and consider municipal bond-duration trim by 25–50bps to hedge fiscal risk.